Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

Bristol Myers Squibb (NYSE: BMY, “BMS”), a leader in biopharmaceuticals, has announced plans to expand its computing infrastructure by deploying an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems. This initiative will provide BMS with the most powerful and energy-efficient NVIDIA infrastructure in life sciences.

The upgraded Vera Rubin infrastructure will significantly enhance BMS’s scientific and computational capabilities, offering up to ten times greater performance per megawatt compared to its predecessor. This advancement will enable BMS to handle larger and more complex AI workloads without a corresponding increase in energy use.

This investment builds on nearly three years of collaboration that began with BMS's initial deployment of NVIDIA DGX SuperPOD infrastructure to support its Research and Development efforts. It marks an important step in scaling BMS's AI-driven scientific programs across various fields, including oncology, hematology, cardiovascular, immunology, and neuroscience.

“BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations,” said Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. “We're committed to translating AI into real outcomes for patients which requires infrastructure built to match that ambition. Expanding our compute capabilities with NVIDIA gives our researchers and teams across the business the scale they need to keep BMS at the leading edge of what AI can do for drug discovery & development.”

BMS’s focus on AI-powered research is already transforming its approach to medicine discovery. For example, AI agents that automate target identification and validation are saving BMS scientists significant time, allowing them to concentrate on hypothesis testing and critical scientific decisions. Additionally, through the company's “Predict First” approach, AI-generated predictions guide experimental design, impacting both small and large molecule programs. This strategy illustrates BMS’s commitment to creating an integrated, AI-powered learning system that enhances decision-making throughout the drug development process.

“Drug discovery is a sequence of decisions made under uncertainty, and better decisions come from better evidence, faster,” said Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb. “This infrastructure lets us learn from every experiment and every clinical readout to sharpen the next hypothesis, allowing BMS scientists to spend less time on manual work and more time on the questions that require human judgment. The goal isn't speed for its own sake; it's raising the probability that each program we advance is the right one.”

This expanded agreement highlights BMS’s vision of hybrid intelligence, where AI systems and human researchers collaborate closely. The Vera Rubin cluster will support this model by providing the computational backbone necessary for developing next-generation foundation models that leverage BMS's extensive proprietary data. It will also utilize domain-specific tools from BioNeMo, NVIDIA's biological AI platform, enabling researchers to evaluate hypotheses at an unprecedented scale.

“BMS has built decades of extraordinary scientific knowledge across some of the most complex areas of human disease,” noted Rory Kelleher, Senior Director of Business Development, Healthcare and Life Sciences at NVIDIA. “With NVIDIA Vera Rubin and BioNeMo Agent Toolkit, BMS has the ability to transform that enterprise scientific data into proprietary intelligence and give agents domain-specific tooling that help scientists explore biology, design molecules and evaluate hypotheses at unprecedented scale — reinventing how medicines are discovered and developed.”

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development, and commercialization of pharmaceutical products and the strategic agreement with NVIDIA. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans, and objectives and involve inherent risks, assumptions, and uncertainties, including internal or external factors that could delay, divert, or change any of them in the next several years, that are difficult to predict, may be beyond our control, and could cause our future financial results, goals, plans, and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties, and other factors include, among others, that the expected benefits of, and opportunities related to, the agreement may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, and risks related to the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risk.

No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise.